$-11.68
(Market cap
$2,525 Mln
Revenue (TTM)
$717 Mln
P/E Ratio
--
P/B Ratio
19.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-6.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-6.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-5.8
-
Face value
--
-
Shares outstanding
98,588,873
10 Years Aggregate
CFO
$-2,527.56 Mln
EBITDA
$-3,583.79 Mln
Net Profit
$-3,308.42 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ultragenyx (RARE)
| -35.4 | -40.4 | -31.8 | -53.6 | -26.7 | -31.9 | -13.7 |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ultragenyx (RARE)
| -45.3 | -11.9 | 3.2 | -44.9 | -39.3 | 224.1 | -1.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ultragenyx (RARE)
|
14.9 | 2,524.9 | 716.9 | -586.4 | -70.6 | -- | -- | 19.7 |
| 86.5 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 271.1 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 74.0 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.1 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.8 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 371.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 542.6 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 593.4 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 355.2 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Ultragenyx (RARE)
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America,... Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California. Read more
-
Founder, President, CEO & Director
Dr. Emil D. Kakkis M.D., Ph.D.
-
Founder, President, CEO & Director
Dr. Emil D. Kakkis M.D., Ph.D.
-
Headquarters
Novato, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Ultragenyx (RARE)
What is the current share price of Ultragenyx (RARE) Today?
The share price of Ultragenyx (RARE) is $14.85 (NASDAQ) as of 03-Sep-2026 16:29 EDT. Ultragenyx (RARE) has given a return of -26.75% in the last 3 years.
What is the current PB & PE ratio of Ultragenyx (RARE)?
Since, TTM earnings of Ultragenyx (RARE) is negative, P/E ratio is not available.
The P/B ratio of Ultragenyx (RARE) is 19.68 times as on 28-Aug-2026, a 280 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-4.00 |
-28.72 |
2024 |
-7.07 |
15.77 |
2023 |
-6.39 |
14.08 |
2022 |
-4.59 |
9.22 |
2021 |
-12.70 |
6.25 |
What is the 52 Week High and Low of Ultragenyx (RARE)?
The 52-week high and low of Ultragenyx (RARE) are Rs 39.89 and Rs 13.81 as of 04-Sep-2026.
What is the market cap of Ultragenyx (RARE)?
Ultragenyx (RARE) has a market capitalisation of $ 2,525 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Ultragenyx (RARE)?
Before investing in Ultragenyx (RARE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.